Review Evaluates Modern Evidence for Robotic and Advanced Colorectal Cancer Surgery
Review Evaluates Modern Evidence for Robotic and Advanced Colorectal Cancer Surgery
A structured narrative review published on November 7, 2026, examines surgical research from January 2024 to July 2026 regarding robotic colorectal cancer surgery.
Full article
Article text is not available for this item. Read it at the original source.
Read full article at sourcebioengineer.org · Opens in a new tab; source language may differ.
The review synthesizes evidence from randomized controlled trials and registry analyses to evaluate the clinical efficacy, functional outcomes, and cost-effectiveness of robotic versus laparoscopic colorectal surgery, noting that while specific scenarios show advantages in oncological control and nerve preservation, universal superiority remains unsupported by current data.
What the source reports
Publisher-reported claims, with original evidence. These results have not been independently verified by RoboSignal.
- paper: not_reported
Source excerpts and review record
Automatically extracted; no manual editorial approval recorded.
inoma classified as cT1 to cT3 with N0 to N1, or ycT1 to ycT3 with Nx disease. In this trial, robotic total mesorectal excision demonstrated superior oncological efficacy, achieving a significantly lower 3-year locoregional recurrence rate of 1.6 percent compared with 4.0 percent in the laparoscopic cohort, alongside a significantly higher 3-year disease-free survival rate of 87.2 percent versus 83.4 percent. Overall
Open source S7
survival at three years did not differ significantly between the arms, recording 94.7 percent in the robotic group and 93.0 percent in the laparoscopic group. In addition to oncological control, the REAL trial documented meaningful early functional benefits associated with robotic rectal resection. Patients assigned to robotic surgery experienced significantly better urinary function, sexual function across both mal
Open source S8
esection margin positivity rate of 4.6 percent, and a grade III to IV complication rate of 6.3 percent. On an epidemiological scale, an analysis of the Medical Data Vision database encompassing 28,711 patients with stage I to III rectal cancer documented 5-year overall survival rates of 95 percent following robotic surgery, 89 percent after laparoscopic resection, and 81 percent after open operations, with correspond
Open source S12
Source：Surgical robotics — News discovery · bioengineer.org